Magnesium compositions and uses thereof for metabolic disorders
A composition for administration to a subject, such as oral administration to a subject, for example, has been provided. Such a composition may comprise at least one magnesium-counter ion compound. A magnesium-counter ion composition described herein may be useful for any of a variety of applications provided herein, such as maintaining, enhancing, and/or improving health, nutrition, and/or another condition of a subject, and/or cognitive, learning, and/or memory function. A magnesium-counter ion composition provided herein may be useful for administration to a subject presenting magnesium deficiency, mild cognitive impairment, Alzheimer's disease, attention deficit hyperactivity disorder, ALS, Parkinson's disease, diabetes, migraine, anxiety disorder, mood disorder, and/or hypertension. A kit, method, and other associated technology are also provided.
1. A method of ameliorating an effect of a metabolic disorder comprising administering to a subject in need for supplementing a magnesium-containing compound in an amount that is effective to ameliorate said effect of the metabolic disorder, wherein the magnesium-containing compound comprises magnesium threonate.
2. The method of claim 1 , further comprising measuring a body fluid concentration of magnesium in the subject after fasting for at least about twelve hours, wherein said body fluid concentration is serum concentration, plasma concentration, or cerebrospinal fluid concentration.
3. The method of claim 1 , wherein said magnesium-containing compound is magnesium-supplemented foodstuff.
4. The method of claim 1 , wherein said metabolic disorder is diabetes.
5. The method of claim 1 , wherein said magnesium-containing compound is administered for a period of greater than about 1 month.
6. A method of therapeutic or prophylactic treatment of a magnesium deficiency-caused metabolic disorder, the method comprising:
administering to a subject in need of a therapeutic or prophylactic treatment of said metabolic disorder, magnesium threonate in an amount that is effective for the therapeutic or prophylactic treatment of the metabolic disorder for at least about 15 days.
7. The method of claim 6 , wherein magnesium threonate is administered for at least about 1 month.
8. The method of claim 6 , wherein magnesium threonate is administered for at least about 4 months.
9. The method of claim 6 , further comprising measuring a body fluid concentration of magnesium in the subject after fasting for at least about 8 hours, wherein said body fluid concentration is serum concentration, plasma concentration, or cerebrospinal fluid concentration.
10. The method of claim 6 , wherein the subject is an adult.